Updated: Alnylam promotes longtime exec Kevin FitzGerald to CSO; Intellia Therapeutics brings on Laura Sepp-Lorenzino
→ Kevin FitzGerald has been with Alnylam since 2005, and with his experience of “leading successful teams on delivery technologies, target selection, and programs in clinic,” he’s been promoted to CSO of the company.
“Our technology is at such an exciting stage and there are so many applications for patients in need, prioritizing what we do first (and at times, what we do not do) will be a very important challenge,” said FitzGerald via email.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
